Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
55%
Lung Cancer
37%
Neoplasm
30%
Protein Tyrosine Kinase Inhibitor
21%
Osimertinib
21%
Overall Survival
20%
Progression Free Survival
16%
Disease
13%
Chemotherapy
12%
Crizotinib
12%
Biological Marker
11%
Adverse Event
11%
Anaplastic Lymphoma Kinase
11%
Afatinib
10%
Cohort Study
8%
Alectinib
7%
Malignant Neoplasm
7%
Erlotinib
7%
Immunotherapy
6%
Anaplastic Lymphoma Kinase Inhibitor
5%
Randomized Controlled Trial
5%
Combination Therapy
5%
Circulating Tumor DNA
5%
Chemoradiation Therapy
5%
Palbociclib
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
80%
Epidermal Growth Factor Receptor
39%
Neoplasm
30%
Lung Cancer
24%
Exon
23%
Targeted Therapy
16%
Overall Survival
13%
Tyrosine-Kinase Inhibitor
13%
Biological Marker
12%
Adverse Event
11%
Osimertinib
11%
Progression Free Survival
11%
Crizotinib
10%
Malignant Neoplasm
9%
Immunotherapy
8%
Non-Small Cell Lung Cancer
8%
Resistance Mutation
8%
Anaplastic Lymphoma Kinase
8%
Disease
7%
Biopsy
7%
Lorlatinib
7%
Radiation Therapy
5%
Chemoradiotherapy
5%
ALK Inhibitor
5%
Metastatic Carcinoma
5%
Lung Nodule
5%
Molecular Imaging
5%
Durvalumab
5%
Palbociclib
5%
Hazard Ratio
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
25%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
14%
Epidermal Growth Factor Receptor
10%
Predictive Biomarker
9%
Targeted Therapy
8%
Biomarker Testing
8%
Exon 20
7%
Molecular Tumor Board
7%
EGFR mutation
7%
Overall Survival
6%
Non-small Cell Lung Cancer Patients
6%
Netherlands
6%
Adverse Events
5%
Atezolizumab
5%
Mutational Profile
5%
